Relapse after stage I melanoma carries a heavier burden, mesenchymal stem cells in atopic dermatitis remain early, and a diabetic foot ulcer guideline is revised

The edition in brief

In the Spanish Melanoma Registry (2018 to 2024), 365 patients treated first line for metastatic melanoma were grouped by primary stage: 58 stage I, 32 IIA, 80 IIB/C and 195 III. Median time to relapse was 52 months after stage I against 25 months after stage III. At relapse, previous stage I patients more often had brain metastases (OR 4.02, 95% CI 2.13-7.58), three or more metastatic sites (OR 1.89) and raised LDH (OR 2.19), and median overall survival was shorter (19.8 months) than after stage IIA (60.1), IIB/C (32.6) or III (43.0); the registry includes only patients who relapsed. A meta-analysis of five small trials (236 participants) of mesenchymal stem cells in moderate to severe atopic dermatitis reported pooled EASI-50 of 46.8% at week 12 and EASI-75 of 17.4% at week 12, with large uncertainty and no placebo-adjusted estimate. A 75-patient randomised trial in erythematotelangiectatic rosacea reported that a moisturiser added to oral minocycline reduced redness measures and improved quality of life over 28 days. The Japanese Dermatological Association has published a third edition of its diabetic foot ulcer and gangrene guideline, weakly recommending imaging for osteomyelitis, negative-pressure wound therapy and platelet-rich plasma.